Cantargia

Investment summary

Cantargia is developing antibodies against IL1RAP. In December 2019 it reported interim data from the ongoing three-arm Phase IIa study with CAN04 in combination with first-line chemotherapy in non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC). Four out of seven evaluable PDAC patients achieved partial response and two out of three evaluable NSLC patients achieved an objective response (one complete and one partial). The results compare favourably to historical response rates to standalone chemotherapy regimens (23% in PDAC; 22–28% in first-line NSCLC). The FDA has also approved Cantargia’s IND application for a Phase Ib trial in the US with CAN04 in combination with a CPI. CAN10 is a preclinical project in inflammation uniquely targeting three interleukins, IL-1, IL-33 and IL-36. In February 2020, Cantargia raised SEK410m, an impressive amount of capital for a pure-play European biotech.